Aktienanalyse zu Fractyl Health Inc (GUTS)GUTSFractyl Health Inc

Fractyl Health, Inc. is a metabolic therapeutics company. The Company is focused on developing new approaches to the treatment of metabolic diseases, including obesity and type 2 diabetes (T2D). The Company’s lead product candidate, Revita, is designed to remodel the duodenal lining via hydrothermal ablation (i.e. duodenal mucosal resurfacing) to reverse damage to intestinal nutrient sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets that are a root cause of metabolic disease. The Revita clinical program is focused on patients living with obesity who want to maintain their weight loss after GLP-1 drug discontinuation. The Company’s Rejuva platform focuses on developing adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Fractyl Health Inc (GUTS) is not a good buy right now due to significant recent declines and ongoing financial struggles. The current price is $0.66, which is down 70.71% year-to-date. The stock has an RSI of 35.099, indicating it is oversold, but this is not a strong enough signal to outweigh the risks. The company reported a net income loss of $25,538,000 in Q2 2026, and the forward P/E ratio is 0, highlighting a lack of profitability. The main risk is the class action lawsuit filed against the company, which could further impact investor confidence and stock performance.